Download free PDF

Transdermal Drug Delivery Systems Market Size & Share 2023 to 2032

Market Size by Type (Transdermal Patches, Transdermal Semisolids) by Application (Pain Management, Hormonal Applications, Central Nervous System Disorders.

Report ID: GMI5548
   |
Published Date: April 2023
 | 
Report Format: PDF

Download Free PDF

Transdermal Drug Delivery System Market Size

Transdermal Drug Delivery System Market size amassed over USD 29 billion in revenue in 2022. The industry is anticipated to witness over 8% CAGR between 2023 and 2032, owing to a remarkable surge in incidences of chronic ailments.

Transdermal Drug Delivery Systems Market Key Takeaways

Market Size & Growth

  • 2022 Market Size: USD 29 Billion
  • 2032 Forecast Market Size: USD 61 Billion
  • CAGR (2023–2032): 8%

Key Market Drivers

  • Increasing prevalence of chronic diseases.
  • Increasing adoption of transdermal patches.
  • Growing demand for non-invasive drug delivery system.

Challenges

  • Limited number of approved medications.
  • High cost involved in development of drug delivery systems.

Transdermal Drug Delivery System Market

expenditure on health and boosted investments in R&D projects focused on enhancing medicine and route of administration. For instance, the Centers for Disease Control and Prevention data suggests that chronic diseases are one of the prime drivers of annual healthcare costs of $4.1 trillion in the U.S. These factors, in line with the continuous technological developments in the drug delivery system, will augment market share.
 

In contrast, the limited number of approved medications and transdermal drug delivery systems worldwide may hamper industry performance. Also, the transdermal treatment route is not considered suitable as it may cause drug irritation or skin sensitivity, hindering the market landscape. Alongside the development, recall, and failure of a transdermal drug delivery system (TDDS) associate high costs, which may further act as a growth restraint over the forecast timeframe.
 

Transdermal Drug Delivery System Market Analysis

Global Transdermal Drug Delivery Systems Market Size, By Type

With respect to type, the transdermal patches segment of the transdermal drug delivery system market is expected to garner over USD 35.5 billion by 2032. Patches are classified into matrix patches, drug-in-adhesive patches, microneedle patches, and reservoir membrane patches. The increasing prevalence of several chronic conditions, such as cardiovascular diseases, cancer, and others, will supplement the market progress.
 

 

Global Transdermal Drug Delivery Systems Market Size, By Application

Transdermal drug delivery system market from the pain management segment is poised to record a valuation of over USD 19.5 billion by 2032. Opioid patches are extensively used in pain management applications, spurring market growth. Furthermore, the increasing prevalence of cancer, resulting in the accelerated embracing of pain patches.
 

 

Transdermal drug delivery system market from hospitals segment is likely to emerge as a major consumer of transdermal drug delivery systems, accounting for over USD 17 billion by 2032. A large patient population undergoing treatment for a variety of disorders will accelerate product adoption across hospital settings. Furthermore, the availability of a wide range of medical services in these establishments will transform business dynamics.
 

 

North America Transdermal Drug Delivery Systems Market

North America transdermal drug delivery system market accumulated over 46.% of revenue share in 2022 and is speculated to attain a healthy CAGR through 2032. Growing adoption of unhealthy lifestyles among individuals, such as alcohol consumption, smoking, and lack of exercise, will boost the disease rate, thereby fostering the market trends.
 

Transdermal Drug Delivery System Market Share

Key players in the transdermal drug delivery system market are:

  • Novartis
  • Mylan
  • Amneal Pharmaceuticals Inc
  • Zydus Pharmaceuticals, Inc
  • UCB
  • Hisamitsu Pharmaceutical Co Inc
  • Corium Inc
  • Micropoint Technologies
  • Sparsha Pharma International Pvt. Ltd.,
  • Luye Pharma.

Companies operating in this business vertical are indulging strategic associations and drug R&D projects to strengthen their market standing.
 

Impact of the COVID-19 pandemic

The COVID-19 pandemic had a damaging impact on the transdermal drug delivery system industry. The stringent lockdown measures implemented by numerous governments worldwide created a huge gap in product demand and supply, thus, resulting in a decline in the sales of transdermal drug delivery systems. Furthermore, reduced patient visits to the hospital due to delays and cancellation of elective medical procedures further limited product uptake, thus, impacting the trade dynamics during the crisis.
 

The transdermal drug delivery system market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

By Type

  • Patches
    • Drug-In-Adhesive Patches
    • Matrix Patches
    • Reservoir Membrane Patches
    • Microneedle Patches
  • Semisolids
    • Gels
    • Ointments
    • Sprays

By Application

  • Pain Management
  • Hormonal Applications
  • Central Nervous System Disorders
  • Cardiovascular Diseases
  • Others

By End-use

  • Hospitals
  • Clinics
  • Home Care Settings
  • Others 

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Poland
    • Switzerland
    • The Netherlands
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Vietnam
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Peru
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Israel

 

Authors:  Mariam Faizullabhoy, Gauri Wani

Research methodology, data sources & validation process

This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.

Our 6-step research process

  1. 1. Research design & analyst oversight

    At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.

    Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.

  2. 2. Primary research

    Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.

  3. 3. Data mining & market analysis

    Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.

  4. 4. Market sizing

    Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.

  5. 5. Forecast model & key assumptions

    Every forecast includes explicit documentation of:

    • ✓ Key growth drivers and their assumed impact

    • ✓ Restraining factors and mitigation scenarios

    • ✓ Regulatory assumptions and policy change risk

    • ✓ Technology adoption curve parameter

    • ✓ Macroeconomic assumptions (GDP growth, inflation, currency)

    • ✓ Competitive dynamics and market entry/exit expectations

  6. 6. Validation & quality assurance

    The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.

    Our triple-layer validation process ensures maximum data reliability:

    • ✓ Statistical Validation

    • ✓ Expert Validation

    • ✓ Market Reality Check

Trust & credibility

10+
Years in Service
Consistent delivery since establishment
A+
BBB Accreditation
Professional standards & satisfaction
ISO
Certified Quality
ISO 9001-2015 Certified Company
150+
Research Analysts
Across 10+ industry verticals
95%
Client Retention
5-year relationship value

Verified data sources

  • Trade publications

    Security & defense sector journals and trade press

  • Industry databases

    Proprietary and third-party market databases

  • Regulatory filings

    Government procurement records and policy documents

  • Academic research

    University studies and specialist institution reports

  • Company reports

    Annual reports, investor presentations, and filings

  • Expert interviews

    C-suite, procurement leads, and technical specialists

  • GMI archive

    13,000+ published studies across 30+ industry verticals

  • Trade data

    Import/export volumes, HS codes, and customs records

Parameters studied & evaluated

Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →

Frequently Asked Question(FAQ) :
How big is the transdermal drug delivery system market?
Global market for transdermal drug delivery system was worth more than USD 29 billion in 2022 and is poised to exhibit over 8% CAGR during 2023-2032, owing to the mounting burden of chronic health disorders.
What is encouraging the adoption of transdermal patches?
Transdermal patches segment is speculated to be worth over USD 35.5 billion by 2032, given the consistent technological developments in existing drug delivery systems.
Why are transdermal drug delivery systems gaining recognition in pain management applications?
Pain management segment is estimated to reach over USD 19.5 billion by 2032, driven by the rapid surge in the incidences of cancer worldwide.
Which are the major transdermal drug delivery system manufacturers globally?
Major companies in the transdermal drug delivery system market are Novartis, Mylan, Amneal Pharmaceuticals, Inc., Zydus Pharmaceuticals, Inc., UCB, Hisamitsu Pharmaceutical Co., Inc., Corium, Inc., Micropoint Technologies, Sparsha Pharma International Pvt. Ltd., and Luye Pharma.
Transdermal Drug Delivery Systems Market Scope
  • Transdermal Drug Delivery Systems Market Size

  • Transdermal Drug Delivery Systems Market Trends

  • Transdermal Drug Delivery Systems Market Analysis

  • Transdermal Drug Delivery Systems Market Share

Authors:  Mariam Faizullabhoy, Gauri Wani
Explore Our Licensing Options:

Starting at: $2,450

Premium Report Details:

Base Year: 2022

Companies Profiled: 10

Tables & Figures: 334

Countries Covered: 27

Pages: 195

Download Free PDF

We use cookies to enhance user experience. (Privacy Policy)